Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials

Main Article Content

Andrew Blauvelt
Phoebe Rich
Howard Sofen
Jo Lambert
Joe Merola
Mark Lebwohl
Lauren Hippeli
Renata Kisa
Subhashis Banerjee
Alexa Kimball

Keywords

psoriasis, scalp, nail, palmoplantar

Abstract

N/A

References

1. Burke JR, et al. Sci Transl Med. 2019;11:1-16.

2. Wrobleski ST, et al. J Med Chem. 2019;62:8973-8995.

3. Armstrong A, et al.
Presented at the Annual Meeting of the American Academy of Dermatology; April 23-25, 2021.

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 > >>